TD Cowen Reaffirms Their Buy Rating on Amicus (FOLD)
In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Amicus (FOLD – Research Report), with a price target of $20.00.
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.88 Average Target Price from Analysts
Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports ...
News Medical on MSN4d
Ariceum Therapeutics receives FDA’s Orphan Drug Designation for targeted radionuclide cancer treatment
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...
Zacks.com on MSN1d
Amicus Therapeutics (FOLD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Wall Street expects a year-over-year increase in earnings on higher revenues when Amicus Therapeutics (FOLD) reports results for the quarter ended December 2024. While this widely-known consensus ...
pharmaphorum6d
Amicus' oral Fabry disease drug approved in US
Amicus Therapeutics’ first oral drug for the rare condition Fabry disease has been approved by the FDA, giving patients an alternative to conventional injected enzyme replacement therapy.
MarketWatch1d
Akero Therapeutics Inc.
Roche Holding AG Akt 1.04% CHF232.83B ...
Slate6d
Trying To Undo A Coup, In The Courts
This week saw an unbroken string of legal losses for Trump and Musk. But will losing in court slow their roll? We're sorry, but something went wrong while fetching ...